FDA Approves Dato-DXd in HR+, HER2- Breast Cancer Following TROPION-Breast01
Virginia G. Kaklamani, MD, DSc, professor of medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center San Antonio, discusses findings from the phase 3 TROPION-Breast01 trial (NCT05104866) of datopotamab …